D'AMATO DAPHNE

Cristoferi, L., D'Amato, D., Maino, C., Bernasconi, D., Dinelli, M., Malandrin, S., et al. (2026). Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. BMJ OPEN, 16(1) [10.1136/bmjopen-2025-106630]. Dettaglio

Cristoferi, L., Maino, C., Bernasconi, D., Ripamonti, I., Scaravaglio, M., Savino, A., et al. (2025). Radiomics-Based Prognostication in Primary Sclerosing Cholangitis: A Proof-of-Concept Study. LIVER INTERNATIONAL, 45(11) [10.1111/liv.70348]. Dettaglio

Cristoferi, L., Porta, M., Bernasconi, D., Leonardi, F., Gerussi, A., Mulinacci, G., et al. (2023). A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. DIGESTIVE AND LIVER DISEASE, 55(3 (March 2023)), 373-380 [10.1016/j.dld.2022.10.015]. Dettaglio

Overi, D., Carpino, G., Cristoferi, L., Onori, P., Kennedy, L., Francis, H., et al. (2022). Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis. JHEP REPORTS, 4(11 (November 2022)) [10.1016/j.jhepr.2022.100556]. Dettaglio

Cordell, H., Fryett, J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., et al. (2022). Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) [Altro] [10.1016/j.jhep.2021.11.015]. Dettaglio